公司资料
Nuvalent 股价、新闻与催化剂
- 股票代码:
- NUVL
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
目前无法获取 NUVL 的收盘价变动背景。
公司概览
Precision Oncology Company
Nuvalent develops highly selective small-molecule kinase inhibitors for cancers with established oncogenic drivers. Its design strategy aims to overcome resistance mutations, penetrate the central nervous system, avoid off-target toxicities, and produce durable responses in patients with advanced solid tumors.
ROS1 Program
Zidesamtinib is a ROS1-selective inhibitor developed for ROS1-positive non-small cell lung cancer, including tumors with resistance mutations and brain metastases. The program includes an initial application for previously treated patients and a label-expansion strategy for patients who have not received a prior ROS1 inhibitor.
ALK Program
Neladalkib is an ALK-selective, TRK-sparing inhibitor designed for advanced ALK-positive non-small cell lung cancer. Development spans previously treated patients and the Phase 3 ALKAZAR study comparing neladalkib with alectinib in the first-line setting.
HER2 and Discovery Pipeline
NVL-330 targets HER2 alterations and is being evaluated in the HEROEX-1 Phase 1 study. Earlier discovery programs apply Nuvalent's structure-based chemistry approach to additional validated kinase targets where existing therapies are limited by resistance, brain penetration, or tolerability.
Acquisition by GSK
GSK subsequently agreed to acquire Nuvalent, adding the company's precision-oncology portfolio and kinase-design capabilities to a larger global oncology organization. The transaction links Nuvalent's late-stage assets with GSK's regulatory, manufacturing, and commercial infrastructure.
未来催化剂
- FDA PDUFA decision for zidesamtinib in previously treated ROS1-positive non-small cell lung cancer on September 18, 2026.
- Submission of data supporting a zidesamtinib label expansion in TKI-naive ROS1-positive non-small cell lung cancer in the second half of 2026.
- FDA review of the submitted NDA for neladalkib in previously treated ALK-positive non-small cell lung cancer.
- Disclosure of a new development candidate by year-end 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。